Embecta (EMBC) CL King's 22nd Annual Best Ideas Conference 2024 summary

Product innovation and development

• Received clearance for a fully disposable open loop insulin pump with a 300-unit reservoir, designed for both Type 1 and Type 2 diabetes, with features aimed at simplifying use and improving adoption.

• Current shelf life is six months, with ongoing work to extend it to 12–18 months through additional testing and regulatory submissions.

• Working towards enabling a bring-your-own-device (BYOD) app for pump control, with a projected timeline of about 1.5 years due to required development, validation, and regulatory steps.

• No plans for a full-scale commercial launch of the open loop pump; focus remains on developing a closed-loop system, with measured testing possible for the open loop.

• Closed-loop pump development involves integrating a 510(k)-cleared algorithm and CGM data, with a multi-site clinical trial expected to enroll hundreds of patients over a couple of years.

Financial strategy and capital allocation

• Significant investments have been made in corporate infrastructure post-spin, including ERP, logistics, and shared services, with most major implementations completed.

• Remaining separation work includes distribution and ERP in Latin America and India, and a global brand transition, with related spending expected to drop to about one-third of current levels in the next year.

• Free cash flow is projected to improve significantly in 2025 and 2026 as one-time separation costs decline.

• Debt reduction is a priority, with plans to pay down more than just mandatory amounts as cash flow improves.

• Considering portfolio expansion, including potential diversification beyond diabetes, leveraging strengths in high-volume medical devices and emerging markets.

Core business trends and market dynamics

• Insulin prescriptions in the U.S. have remained stable, with a shift from vials to pens; pen needle business is stable to growing, offsetting declines in syringes.

• Syringe business, now a low double-digit percentage of revenue, continues to decline, mainly in the U.S., due to the shift to pens and demographic changes.

• Margins are higher in pen needles than syringes, and the mix shift benefits profitability.

• GLP-1 adoption has not caused dramatic changes in the core business; pen needles are compatible with GLP-1 pen injectors, presenting new growth opportunities, especially with small pack launches in Germany.

• Monitoring the impact of once-weekly insulin, with adoption dependent on cost, payer coverage, and real-world evidence, but no immediate impact expected.